Javelin strikes deal with Baxter

Javelin Pharmaceuticals Inc., based in Cambridge, said it will expand its relationship with Baxter Healthcare Corp. to expand manufacturing for Javelin's drug to treat post-operative pain.

The agreement between the two companies will provide more manufacturing capacity for Dyloject, which is currently marketed in the United Kingdom and undergoing trials in the United States.

The drug is an injectable form of diclofenac sodium, a widely used anti-inflammatory medicine.
(By Elizabeth Campbell, Globe correspondent)